PASSAGE BIO, INC. Financing Cash Flow
PASSAGE BIO, INC. (PASG) reported Financing Cash Flow of $23.00 thousand for the 12-month period ending 2025-12-31, per its S-4/A filed 2026-09-03.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-09-03
- PASSAGE BIO, INC. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $9.00K, a 80.85% decline year-over-year.
- PASSAGE BIO, INC. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $0.00.
- PASSAGE BIO, INC. net cash provided by (used in) financing activities for the quarter ending 2024-12-31 was $47.00K, a 2.17% increase year-over-year.
- PASSAGE BIO, INC. net cash provided by (used in) financing activities for the quarter ending 2024-09-30 was $0.00.
- PASSAGE BIO, INC. net cash provided by (used in) financing activities for fiscal 2023 was $135.00K.
- PASSAGE BIO, INC. net cash provided by (used in) financing activities for fiscal 2022 was -$1.35M, a 100.81% decline from fiscal 2021.
- PASSAGE BIO, INC. net cash provided by (used in) financing activities for fiscal 2021 was $166.66M, a 27.15% decline from fiscal 2020.
- PASSAGE BIO, INC. net cash provided by (used in) financing activities for fiscal 2020 was $228.75M, a 30.27% increase from fiscal 2019.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2025-12-31 | $9.00K derived: S-4/A 12 month − 10-Q 9 month · filed 2026-09-03 | $9.00K derived: sum of 2 quarters · filed 2026-09-03 | $23.00K S-4/A · filed 2026-09-03 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − S-4/A 6 month · filed 2025-11-10 | $14.00K 10-Q · filed 2025-11-10 | ||
| 2025-06-30 | $14.00K S-4/A · filed 2026-09-03 | |||
| 2024-12-31 | $47.00K derived: S-4/A 12 month − 10-Q 9 month · filed 2026-09-03 | $47.00K derived: sum of 2 quarters · filed 2026-09-03 | $132.00K derived: sum of 3 quarters · filed 2026-09-03 | $8.87M S-4/A · filed 2026-09-03 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $85.00K derived: sum of 2 quarters · filed 2025-11-10 | $8.83M 10-Q · filed 2025-11-10 | $8.87M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $85.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $8.83M 10-Q · filed 2025-08-12 | $8.87M derived: sum of 3 quarters · filed 2025-08-12 | $8.87M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $8.74M 10-Q · filed 2025-05-13 | $8.79M derived: sum of 2 quarters · filed 2025-05-13 | $8.79M derived: sum of 3 quarters · filed 2025-05-13 | |
| 2023-12-31 | $46.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | $46.00K derived: sum of 2 quarters · filed 2025-03-04 | $135.00K 10-K · filed 2025-03-04 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $89.00K 10-Q · filed 2024-11-13 | ||
| 2023-06-30 | $89.00K 10-Q · filed 2024-08-08 | |||
| 2022-12-31 | -$588.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-04 | -$996.00K derived: sum of 2 quarters · filed 2024-03-04 | -$1.40M derived: sum of 3 quarters · filed 2024-03-04 | -$1.35M 10-K · filed 2024-03-04 |
| 2022-09-30 | -$408.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$814.00K derived: sum of 2 quarters · filed 2023-11-13 | -$765.00K 10-Q · filed 2023-11-13 | -$310.00K derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | -$406.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | -$357.00K 10-Q · filed 2023-08-07 | $98.00K derived: sum of 3 quarters · filed 2023-08-07 | $142.00K derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | $49.00K 10-Q · filed 2023-05-11 | $504.00K derived: sum of 2 quarters · filed 2023-05-11 | $548.00K derived: sum of 3 quarters · filed 2023-05-11 | $1.07M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $455.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $499.00K derived: sum of 2 quarters · filed 2023-03-06 | $1.02M derived: sum of 3 quarters · filed 2023-03-06 | $166.66M 10-K · filed 2023-03-06 |
| 2021-09-30 | $44.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $567.00K derived: sum of 2 quarters · filed 2022-11-10 | $166.20M 10-Q · filed 2022-11-10 | $166.60M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $523.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $166.16M 10-Q · filed 2022-08-04 | $166.56M derived: sum of 3 quarters · filed 2022-08-04 | $166.60M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $165.63M 10-Q · filed 2022-05-16 | $166.04M derived: sum of 2 quarters · filed 2022-05-16 | $166.08M derived: sum of 3 quarters · filed 2022-05-16 | $164.48M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $402.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $446.00K derived: sum of 2 quarters · filed 2022-03-03 | -$1.15M derived: sum of 3 quarters · filed 2022-03-03 | $228.75M 10-K · filed 2022-03-03 |
| 2020-09-30 | $44.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | -$1.55M derived: sum of 2 quarters · filed 2021-11-04 | $228.35M 10-Q · filed 2021-11-04 | $227.55M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | -$1.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $228.31M 10-Q · filed 2021-08-05 | $227.51M derived: sum of 3 quarters · filed 2021-08-05 | $337.45M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $229.90M 10-Q · filed 2021-05-05 | $229.10M derived: sum of 2 quarters · filed 2021-05-05 | $339.04M derived: sum of 3 quarters · filed 2021-05-05 | $385.35M derived: sum of 4 quarters · filed 2021-05-05 |
| 2019-12-31 | -$799.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-03 | $109.14M derived: sum of 2 quarters · filed 2021-03-03 | $155.44M derived: sum of 3 quarters · filed 2021-03-03 | $175.60M 10-K · filed 2021-03-03 |
| 2019-09-30 | $109.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $156.24M derived: sum of 2 quarters · filed 2020-11-10 | $176.40M 10-Q · filed 2020-11-10 | |
| 2019-06-30 | $46.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-13 | $66.46M 10-Q · filed 2020-08-13 | ||
| 2019-03-31 | $20.16M 10-Q · filed 2020-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |